1021438-07-2Relevant academic research and scientific papers
Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease
Rudd, Michael T.,McCauley, John A.,Romano, Joseph J.,Butcher, John W.,Bush, Kimberly,McIntyre, Charles J.,Nguyen, Kevin T.,Gilbert, Kevin F.,Lyle, Terry A.,Holloway, M. Katharine,Wan, Bang-Lin,Vacca, Joseph P.,Summa, Vincenzo,Harper, Steven,Rowley, Michael,Carroll, Steven S.,Burlein, Christine,Dimuzio, Jillian M.,Gates, Adam,Graham, Donald J.,Huang, Qian,Ludmerer, Steven W.,McClain, Stephanie,McHale, Carolyn,Stahlhut, Mark,Fandozzi, Christine,Taylor, Anne,Trainor, Nicole,Olsen, David B.,Liverton, Nigel J.
supporting information, p. 7201 - 7206 (2013/01/15)
A series of macrocyclic compounds containing 2-substituted-quinoline moieties have been discovered and shown to exhibit excellent HCV NS3/4a genotype 3a and genotype 1b R155K mutant activity while maintaining the high rat liver exposure. Cyclization of the 2-substituted quinoline substituent led to a series of tricyclic P2 compounds which also display superb gt3a potency.
HCV NS3 PROTEASE INHIBITORS
-
Page/Page column 28; 46, (2008/12/05)
The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections. (I)
